trifluoperazine has been researched along with Brain Neoplasms in 14 studies
Brain Neoplasms: Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We report that radiation induces a glioma-initiating cell phenotype, and we have identified trifluoperazine (TFP) as a compound that interferes with this phenotype conversion." | 7.96 | The dopamine receptor antagonist trifluoperazine prevents phenotype conversion and improves survival in mouse models of glioblastoma. ( Alli, C; Bhat, K; Cheng, F; Cloughesy, TF; Damoiseaux, R; Duhachek-Muggy, S; He, L; Kornblum, HI; Liau, LM; Medina, P; Nghiemphu, PL; Pajonk, F; Pellegrini, M; Saki, M; Vlashi, E; Yu, G; Zemke, NR, 2020) |
| "Repositioning of the antipsychotic drug trifluoperazine for treatment of glioblastoma, an aggressive brain tumor, has been previously suggested." | 7.88 | Repositioning of the antipsychotic trifluoperazine: Synthesis, biological evaluation and in silico study of trifluoperazine analogs as anti-glioblastoma agents. ( Elkamhawy, A; Hassan, AHE; Hong, J; Jeon, B; Kang, S; Kang, SS; Lee, CJ; Lee, JM; Oh, SJ; Paek, SH; Paik, S; Roh, EJ, 2018) |
| "However, brain metastases remain the biggest threat to the survival and quality of life of melanoma patients." | 5.62 | Repurposing of antipsychotic trifluoperazine for treating brain metastasis, lung metastasis and bone metastasis of melanoma by disrupting autophagy flux. ( Lin, W; Xi, H; Xia, Y; Xie, Y; Xiong, M; Xu, F; Xue, Q; Yang, H; Ye, T; Yu, L, 2021) |
| " We report that radiation induces a glioma-initiating cell phenotype, and we have identified trifluoperazine (TFP) as a compound that interferes with this phenotype conversion." | 3.96 | The dopamine receptor antagonist trifluoperazine prevents phenotype conversion and improves survival in mouse models of glioblastoma. ( Alli, C; Bhat, K; Cheng, F; Cloughesy, TF; Damoiseaux, R; Duhachek-Muggy, S; He, L; Kornblum, HI; Liau, LM; Medina, P; Nghiemphu, PL; Pajonk, F; Pellegrini, M; Saki, M; Vlashi, E; Yu, G; Zemke, NR, 2020) |
| "Repositioning of the antipsychotic drug trifluoperazine for treatment of glioblastoma, an aggressive brain tumor, has been previously suggested." | 3.88 | Repositioning of the antipsychotic trifluoperazine: Synthesis, biological evaluation and in silico study of trifluoperazine analogs as anti-glioblastoma agents. ( Elkamhawy, A; Hassan, AHE; Hong, J; Jeon, B; Kang, S; Kang, SS; Lee, CJ; Lee, JM; Oh, SJ; Paek, SH; Paik, S; Roh, EJ, 2018) |
| "Membrane-modifying agents such as reserpine, calcium antagonists (nicardipine, verapamil) and calmodulin inhibitor (trifluoperazine) were found to enhance the cytotoxicity of ACNU in vitro and in vivo in ACNU-resistant C 6 (C 6/ACNU) glioma." | 3.67 | [Possibility of overcoming of ACNU resistance in an ACNU-resistant subline of C6 rat glioma]. ( Mogami, H; Sakamoto, Y; Shimizu, K; Ushio, Y; Yoshida, T, 1986) |
| "A calmodulin inhibitor, trifluoperazine, was found to enhance the cytotoxic action of ACNU in C6, especially in ACNU-resistant (C6/ACNU) glioma cells in vitro." | 3.67 | [Overcoming of ACNU resistance in an ACNU-resistant subline of rat C6 glioma in vivo through enhanced effect of ACNU by calmodulin inhibitor]. ( Egawa, T; Hayakawa, T; Mogami, H; Sakamoto, Y; Shimizu, K; Yoshida, T, 1987) |
| "Glioblastoma multiforme is a fatal malignancy of the central nervous system, demanding new methods of treatment." | 2.67 | The effect of calmodulin inhibitors with bleomycin on the treatment of patients with high grade gliomas. ( Byrne, TN; Choudhury, S; Davis, CA; Durivage, HJ; Gates, JA; Hait, WN; Piepmeier, J, 1990) |
| "However, brain metastases remain the biggest threat to the survival and quality of life of melanoma patients." | 1.62 | Repurposing of antipsychotic trifluoperazine for treating brain metastasis, lung metastasis and bone metastasis of melanoma by disrupting autophagy flux. ( Lin, W; Xi, H; Xia, Y; Xie, Y; Xiong, M; Xu, F; Xue, Q; Yang, H; Ye, T; Yu, L, 2021) |
| "Trifluoperazine (TFP) is an approved antipsychotic drug with good bioavailability in brain and had shown anticancer effect in several types of cancer." | 1.48 | The antipsychotic agent trifluoperazine hydrochloride suppresses triple-negative breast cancer tumor growth and brain metastasis by inducing G0/G1 arrest and apoptosis. ( Feng, Z; Gao, T; Hu, X; Lei, Q; Peng, C; Ran, Z; Wang, Q; Wang, R; Xia, Y; Xie, Z; Xu, F; Xue, Q; Yang, N; Yang, Y; Yu, L; Zeng, Z, 2018) |
| "When trifluoperazine were added along with ACNU to the culture in vitro at a concentration of 10 and 20 microM, ACNU resistance was completely overcome." | 1.27 | [Possibility of overcoming ACNU resistance in ACNU-resistant sublines of rat brain tumors in vitro by a calmodulin inhibitor]. ( Egawa, T; Mogami, H; Sakamoto, Y; Shimizu, K; Yoshida, T, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (28.57) | 18.7374 |
| 1990's | 2 (14.29) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (28.57) | 24.3611 |
| 2020's | 4 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Kang, S | 3 |
| Lee, JM | 1 |
| Jeon, B | 1 |
| Elkamhawy, A | 1 |
| Paik, S | 1 |
| Hong, J | 1 |
| Oh, SJ | 1 |
| Paek, SH | 1 |
| Lee, CJ | 1 |
| Hassan, AHE | 1 |
| Kang, SS | 1 |
| Roh, EJ | 1 |
| Stringer, BW | 1 |
| De Silva, MI | 1 |
| Greenberg, Z | 1 |
| Noreña Puerta, A | 1 |
| Adams, R | 1 |
| Milky, B | 1 |
| Zabolocki, M | 1 |
| van den Hurk, M | 1 |
| Ebert, LM | 1 |
| Fairly Bishop, C | 1 |
| Conn, SJ | 1 |
| Kichenadasse, G | 1 |
| Michael, MZ | 1 |
| Ormsby, RJ | 1 |
| Poonoose, S | 1 |
| Bardy, C | 1 |
| Kwon, HN | 1 |
| Park, S | 1 |
| Bhat, K | 1 |
| Saki, M | 1 |
| Vlashi, E | 1 |
| Cheng, F | 1 |
| Duhachek-Muggy, S | 1 |
| Alli, C | 1 |
| Yu, G | 1 |
| Medina, P | 1 |
| He, L | 1 |
| Damoiseaux, R | 1 |
| Pellegrini, M | 1 |
| Zemke, NR | 1 |
| Nghiemphu, PL | 1 |
| Cloughesy, TF | 1 |
| Liau, LM | 1 |
| Kornblum, HI | 1 |
| Pajonk, F | 1 |
| Xia, Y | 2 |
| Xu, F | 2 |
| Xiong, M | 1 |
| Yang, H | 1 |
| Lin, W | 1 |
| Xie, Y | 1 |
| Xi, H | 1 |
| Xue, Q | 2 |
| Ye, T | 1 |
| Yu, L | 2 |
| Wen, Y | 1 |
| Zhang, Y | 1 |
| Li, J | 1 |
| Luo, F | 1 |
| Huang, Z | 1 |
| Liu, K | 1 |
| Feng, Z | 1 |
| Gao, T | 1 |
| Lei, Q | 1 |
| Peng, C | 1 |
| Yang, Y | 1 |
| Hu, X | 1 |
| Wang, Q | 1 |
| Wang, R | 1 |
| Ran, Z | 1 |
| Zeng, Z | 1 |
| Yang, N | 1 |
| Xie, Z | 1 |
| Ramis, G | 1 |
| Villalonga-Planells, R | 1 |
| Serra-Sitjar, M | 1 |
| Brell, M | 1 |
| Fernández de Mattos, S | 1 |
| Villalonga, P | 1 |
| Cheng, EH | 1 |
| Gorelick, FS | 1 |
| Czernik, AJ | 1 |
| Bagaglio, DM | 1 |
| Hait, WN | 2 |
| Byrne, TN | 1 |
| Piepmeier, J | 1 |
| Durivage, HJ | 1 |
| Choudhury, S | 1 |
| Davis, CA | 1 |
| Gates, JA | 1 |
| Yoshida, T | 3 |
| Shimizu, K | 3 |
| Ushio, Y | 1 |
| Mogami, H | 3 |
| Sakamoto, Y | 3 |
| Egawa, T | 2 |
| Hayakawa, T | 1 |
| Uzunov, P | 1 |
| Shein, HM | 1 |
| Weiss, B | 1 |
1 trial available for trifluoperazine and Brain Neoplasms
| Article | Year |
|---|---|
The effect of calmodulin inhibitors with bleomycin on the treatment of patients with high grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Calmodulin; | 1990 |
13 other studies available for trifluoperazine and Brain Neoplasms
| Article | Year |
|---|---|
Repositioning of the antipsychotic trifluoperazine: Synthesis, biological evaluation and in silico study of trifluoperazine analogs as anti-glioblastoma agents.
Topics: Animals; Antineoplastic Agents; Antipsychotic Agents; Brain; Brain Neoplasms; Calcium; Cell Line, Tu | 2018 |
Human cerebrospinal fluid affects chemoradiotherapy sensitivities in tumor cells from patients with glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Glioblastoma; Humans; Temozolomide; Trifluoper | 2023 |
Interaction between IDH1 WT and calmodulin and its implications for glioblastoma cell growth and migration.
Topics: Amino Acid Sequence; Binding Sites; Brain Neoplasms; Calmodulin; Cell Line, Tumor; Cell Movement; Ce | 2020 |
The dopamine receptor antagonist trifluoperazine prevents phenotype conversion and improves survival in mouse models of glioblastoma.
Topics: Animals; beta Catenin; Brain Neoplasms; Disease Models, Animal; Dopamine Antagonists; Gene Expressio | 2020 |
Repurposing of antipsychotic trifluoperazine for treating brain metastasis, lung metastasis and bone metastasis of melanoma by disrupting autophagy flux.
Topics: Animals; Antineoplastic Agents; Antipsychotic Agents; Autophagy; Bone Neoplasms; Brain Neoplasms; Ce | 2021 |
Low concentration trifluoperazine promotes proliferation and reduces calcium-dependent apoptosis in glioma cells.
Topics: Animals; Antidepressive Agents; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Calcium; Cell Cycle; | 2018 |
The antipsychotic agent trifluoperazine hydrochloride suppresses triple-negative breast cancer tumor growth and brain metastasis by inducing G0/G1 arrest and apoptosis.
Topics: Animals; Antipsychotic Agents; Apoptosis; Brain; Brain Neoplasms; Caspase 3; Cell Cycle Checkpoints; | 2018 |
The tumor suppressor FOXO3a mediates the response to EGFR inhibition in glioblastoma cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; ErbB Receptors; Erlotinib Hydro | 2019 |
Calmodulin-dependent protein kinases in rat glioblastoma.
Topics: Animals; Brain Neoplasms; Calcium; Calcium-Calmodulin-Dependent Protein Kinases; Calmodulin; Gliobla | 1995 |
[Possibility of overcoming of ACNU resistance in an ACNU-resistant subline of C6 rat glioma].
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line; Cells, Cultured; Drug Resistance; Drug T | 1986 |
[Possibility of overcoming ACNU resistance in ACNU-resistant sublines of rat brain tumors in vitro by a calmodulin inhibitor].
Topics: Animals; Brain Neoplasms; Calmodulin; Cell Line; Drug Resistance; Drug Therapy, Combination; In Vitr | 1987 |
[Overcoming of ACNU resistance in an ACNU-resistant subline of rat C6 glioma in vivo through enhanced effect of ACNU by calmodulin inhibitor].
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Calmodulin; Drug Resistance; Glioma; Male; Nimustin | 1987 |
Multiple forms of cyclic 3',5'-AMP phosphodiesterase of rat cerebrum and cloned astrocytoma and neuroblastoma cells.
Topics: Animals; Astrocytoma; Brain; Brain Neoplasms; Cattle; Clone Cells; Cyclic AMP; Dialysis; Drug Stabil | 1974 |